tradmap

ELUT ELUTIA INC.

$0.85 -0.83%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

ELUTIA INC. (ELUT) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $37 million. Shares last traded at $0.85, 64.2% below their 52-week high. Over the past year the stock is down 64.5%. ELUT trades at a price-to-earnings ratio of 0.72, below the Biological Products, (No Diagnostic Substances) median of 22.81. Revenue declined 15.0% year over year.

Market Cap
$37M
Shares Out
43.6M
EPS (TTM)
$-1.65
P/E Ratio
0.72
P/S Ratio
3.07
P/B Ratio
2.36
Dividend / Share
Dividend Yield
52-Week High
$2.38
52-Week Low
$0.50
Volume
9
Avg Vol (3m)
1,578

Performance

1W
-15.55%
1M
-4.16%
3M
-24.52%
6M
-26.47%
YTD
+32.60%
1Y
-64.46%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
41.67
SMA (50)
$0.93
SMA (200)
$0.94
Price vs SMA50
-8.37%
Price vs SMA200
-9.26%
ATR (14)
$0.05

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$12M
Net Income
$52M
Gross Margin
57.8%
Operating Margin
-214.9%
Net Margin
Return on Equity
329.0%
Return on Assets
118.7%
Current Ratio
1.77
Debt / Equity
1.66
Revenue Growth (YoY)
-15.0%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.35 2026-08-14
Q1 2026 $-0.17 2026-05-15
FY 2025 $0.87 2026-03-13
Q3 2025 $-0.66 2025-11-12
Q2 2026 $-0.47 2026-08-14
Q1 2026 $-0.21 2026-05-15

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

ELUT vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/E vs peers
0.72 / 22.81 med
-97% discount
P/S vs peers
3.07 / 19.49 med
-84% discount
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.